Click here to watch Dr. Virginia Devonshire discuss the case and the responses to the survey.
Thomas, 38, is a chemical engineer who initially presented in 2019 with optic neuritis followed two months later by a myelopathic episode. MRI was highly active with two gadolinium-enhancing T1 and multiple T2 lesions. EDSS was 2.5 (optic 1, sensory 2, bladder 2). Thomas had no relevant medical conditions other than obesity; his body weight was 120 kg (BMI 34 kg/m2) at presentation. Read More
SPECIAL REPORT
Long-term treatment with ofatumumab, a fully human anti-CD20 monoclonal antibody, is associated with a favourable safety profile and sustained efficacy, according to a newly-published analysis of the ALITHIOS long-term extension (Hauser et al. Mult Scler 2023; epublished September 11, 2023). The study is the most recent to support the earlier use of high-efficacy therapy in patients with multiple sclerosis. Read More
This year’s joint ECTRIMS-ACTRIMS congress will be held on October 11-13 in Milan, Italy. We are currently surveying readers about their key interests beforehand as a guide to our coverage. Daily highlights will be posted on October 12-14. Click here to complete the survey to tell us what topics are of greatest interest to you. Read More
Help make the NeuroSens coverage of MSMilan 2023 (The 9th Joint ECTRIMS-ACTRIMS Meeting) relevant to you.
Complete the survey below to tell us what topics are of greatest interest to you. Read More